The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Pediatric Uveitis in the Biologic Age: Risk Factors, Treatment & Outcomes

Pediatric Uveitis in the Biologic Age: Risk Factors, Treatment & Outcomes

March 19, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

‘It is very humbling to realize how much more we need to do for our children with uveitis.’ —Sheila T. Angeles-Han, MD, MSc

You Might Also Like
  • Uveitis: Know the Risk Factors, Symptoms & Treatment Options
  • Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
Explore This Issue
March 2019
Also By This Author
  • Gender Disparity in Invited Commentary Authorship

Risk Factors

Sheila T. Angeles-Han, MD, MSc, associate professor of pediatrics and pediatric rheumatologist at Cincinnati Children’s Hospital Medical Center, took the stage to describe the risk factors for, and treatment of, pediatric uveitis. “It is very humbling to realize how much more we need to do for our children with uveitis,” she stated.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Angeles-Han noted the group of children most at risk for uveitis are white females. Severe uveitis, however, is more common in black males. Beyond that, little is known, and ongoing studies are focused on identifying genetic risk factors and biomarkers for the onset of uveitis.

Diagnosis

The diagnosis of uveitis frequently occurs early after a diagnosis of JIA. In fact, the more recent the JIA diagnosis, the higher the risk of developing uveitis, and approximately 50% of patients will develop uveitis in the first year after diagnosis of JIA. This risk of uveitis is one of the reasons early systemic treatment of JIA with methotrexate may, in fact, influence the development of uveitis, Dr. Angeles-Han explained.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Rheumatologists treat uveitis with the goals of achieving sustained remission, preserving vision, and preventing recurrences and new or worsening ocular complications. This should occur with no ocular inflammation and no topical steroids. Instead, uveitis should be treated with corticosteroids (topical, oral) and disease-modifying anti-rheumatic drugs, such as methotrexate, mycophenolate and azathioprine, as well as with biologics.

“There really aren’t any set standardized ways to treat patients with JIA-associated uveitis,” stated Dr. Angeles-Han. Most physicians, she explained, start with methotrexate followed by tumor necrosis factor-α inhibitor (TNFi) therapy. If the patient fails TNFi, then it is possible to escalate the dose, try a different TNFi or start another class of biologic.

Draft 2018 ACR & Arthritis Foundation Guidelines

Some studies have investigated the factors associated with remission and relapse after medication discontinuation.1,2 Although the studies differed by diagnosis, medication and follow-up, they suggested a 43–73% relapse one year after the discontinuation of medication, explained Dr. Angeles-Han.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

She also presented the draft 2018 ACR and Arthritis Foundation guideline for the screening, monitoring and treatment of JIA-associated uveitis. The guideline, she noted, was created by rheumatologists and ophthalmologists working together and contains 19 recommendations, including one for ophthalmologic screening of patients with JIA. The guideline emphasizes the importance of screening for uveitis and monitoring eye disease in this patient population. 

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: 2018 ACR/ARHP Annual Meeting, UveitisIssue: March 2019

You Might Also Like:
  • Uveitis: Know the Risk Factors, Symptoms & Treatment Options
  • Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
  • New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)